Prevalence of MDR pathogens of bacterial meningitis in Egypt and new synergistic antibiotic combinations

Mona M Abdelkader, Khaled M Aboshanab, Marwa A El-Ashry, Mohammad M Aboulwafa, Mona M Abdelkader, Khaled M Aboshanab, Marwa A El-Ashry, Mohammad M Aboulwafa

Abstract

The aim of this study was identifying bacterial pathogens involved in meningitis, studying their antibiotic resistance profiles, investigating the antibiotic resistance genes as well as evaluating the use of various antibiotic combinations. Antibiotic susceptibility tests were evaluated according to CLSI guidelines. Antibiotic combinations were evaluated by calculating the Fractional Inhibitory Concentration (FIC) index. A total of 71 bacterial isolates were recovered from 68 culture positive CSF specimens. Sixty five of these isolates (91.5%) were recovered from single infection specimens, while 6 isolates (8.4%) were recovered from mixed infection specimens. Out of the 71 recovered isolates, 48 (67.6%) were Gram-positive, and 23 (32.4%) were Gram-negative. Thirty one of the Gram positive isolates were S. pneumoniae (64.6%, n = 48). Out of the recovered 71 isolates; 26 (36.6%) were multidrug-resistant (MDR) isolates of which, 18 (69.2%) were Gram-negative and 8 (30.8%) were Gram-positive. All MDR isolates (100%) showed resistance to penicillin and ampicillin, however, they showed lower resistance to meropenem (50%), levofloxacin (50%), amikacin (48%), pipercillin-tazobactam (45.8%). Most common antibiotic resistance genes were investigated including: tem (21.1%), shv (15.8%), ctx-m (15.8%) coding for TEM-, SHV, CTX-M extended-spectrum beta-lactamases (ESBLs), respectively; aac(6')-I b(26.3%) coding for aminoglycoside 6'-N-acetyltransferase type Ib ciprofloxacin resistant variant; and qnrA (5.3%) gene coding for quinolone resistance. The DNA sequences of the respective resistance genes of some selected isolates were PCR amplified, analyzed and submitted to the GenBank database under the accession numbers, KX214665, KX214664, KX214663, KX214662, respectively. The FIC values for ampicillin/sulbactam plus cefepime showed either additive or synergistic effect against ten tested Gram-negative MDR isolates, while doxycycline plus levofloxacin combination revealed synergism against two MDR Gram-positive isolates. The results indicate high prevalence of antibiotic resistance among MDR isolates. Therefore, new guidelines should be implemented in Egypt to rationalize the use and avoid the misuse and abuse of antimicrobial agents.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Relative percentage of various CSF…
Fig 1. Relative percentage of various CSF specimens collected during the study period (n = 1337).
Out of the 68 culture positive specimens, 71 bacterial isolates were recovered from cerebrospinal fluid (CSF); 65 isolates (91.5%) were from specimens with single bacterial species, 6 isolates (8.4%) were from mixed culture. Specimens collected from males were 44(64.7%), while only 24 specimens were collected from females (35.3%). Regarding age, 5 specimens (7.35%) were from infants (age from 1–12 Months), 10 specimens (14.7%) were from children (>1–16 Years) and the rest of the specimens (77.9%) were from adults (>16Years). Using Gram-stain, 48 isolates (67.6%) were found to be Gram-positive and 23 isolates (32.4%) were found to be Gram-negative. The prevalence of different clinical bacterial isolates cultured from the 68 CSF specimens is delineated in Fig 2.
Fig 2. Prevalence of different clinical bacterial…
Fig 2. Prevalence of different clinical bacterial isolates cultured from the 68 CSF specimens.
Prevalence was expressed as percentage from total count (n = 71).
Fig 3. Prevalence of the antimicrobial resistance…
Fig 3. Prevalence of the antimicrobial resistance of the 26 tested MDR isolates to different antimicrobial agents.
Prevalence was expressed as percent of resistant isolates relative to total tested isolates for each antimicrobial agent (n, 26).
Fig 4. Prevalence of some selected antibiotic…
Fig 4. Prevalence of some selected antibiotic resistance genes among MDR bacterial pathogens.

References

    1. Brouwer MC, Tunkel AR, van de Beek D.Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.J ClinMicrobiol.2010; 23(3):467–92.
    1. Rafi W, Chandramuki A, Mani R, Satishchandra P, Krishna S.Rapid diagnosis of acute bacterial meningitis: role of broad range 16S rRNA PCR.J Emerg Med.2010;38(2):225–30. 10.1016/j.jemermed.2008.02.053
    1. Won H, Yang S, Gaydos C, Hardick J, Ramachandran P, Hsieh YH, et al. A broad range assay for rapid detection and etiologic characterization of bacterial meningitis: performance testing in samples from sub-Sahara. J Diagn Microbiol Infect Dis.2012;74(1): 22–27.
    1. Van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351(18):1849–59. 10.1056/NEJMoa040845
    1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal Disease. N Engl J Med.2001;344(18):1378–88. 10.1056/NEJM200105033441807
    1. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000.Lancet. 2012;379(9832):2151–61. 10.1016/S0140-6736(12)60560-1
    1. Van de Beek D. Progress and challenges in bacterial meningitis. Lancet 2012; 380(9854):1623–4. 10.1016/S0140-6736(12)61808-X
    1. Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, et al. Bacterial meningitis in the United States, 1998–2007. N Engl J Med. 2011;364(21): 2016–25. 10.1056/NEJMoa1005384
    1. Van de Beek D, deGans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Me. 2006; 354(1):44–53.
    1. Van de Beek D, Brouwer MC,Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1623–4.
    1. Alekshun MN, LevySB. Molecular mechanisms of antibacterial multidrug resistance.Cell 2007;128(6):1037–50. 10.1016/j.cell.2007.03.004
    1. Gale EF, Cundliffe E, Reynolds P E, Richmond MH, and Waring M. J. (ed.). The molecular basis of antibiotic action, 2nd ed. John Wiley, Chichester, United Kingdom, 1981.
    1. Walsh C. Antibiotics: actions, origins, resistance ASM Press, Washington, DC, 2003.
    1. Davies J, Davies D. Origins and Evolution of Antibiotic Resistance. Microbiol Mol Biol Rev. 2010;74(3):417–33. 10.1128/MMBR.00016-10
    1. Kumar S, Varela MF. Molecular mechanisms of bacterial resistance to antimicrobial agents.Book; Microbial pathogens and strategies for combating them: science, technology and education, book edited by A. Méndez-Vilas, published: December2013, Formatex Research Center. Chapter 56 p 522–534.
    1. CLSI document M100-S21. Performance Standards for Antimicrobials Susceptibility Testing; Twenty-First Informational Supplement. 2011.
    1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18(3): 268–281. 10.1111/j.1469-0691.2011.03570.x
    1. Hsieh MH, Yu CM, Yu VL,Chow JW. Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis. 1993;16(4):343–9.
    1. Sambrook J, Russell D. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press 2001; USA. ISBN: 0-879-69577-3.
    1. Bonnet R, Dutour C, Sampaio JL, Chanal C, Sirot D, Labia R, et al. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240 à Gly.Antimicrob Agents Chemother.2001;45(8): 2269–2275. 10.1128/AAC.45.8.2269-2275.2001
    1. Rasheed JK., Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, et al. Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother. 1997;41(3): 647–653.
    1. Hamed SM., Aboshanab KM, Elkhatib WF, Ashour MS. Aminoglycoside Resistance Patterns of Certain Gram Negative Uropathogens Recovered from Hospitalized Egyptian Patients.British Microbiol Res J 2013;3(4): 448–460.
    1. Abdel-Aziz S, Aboshanab KM, Aboulwafa MM, Hassouna NA. Phenotypic and genotypic studies on antimicrobial resistance of lower respiratory tract bacterial pathogens.ActaMicrobiol.2015;6(1:1)
    1. Staden R. The staden sequence analysis package. Molecular Biotechnology 1996;5(3): 233–41.
    1. Carbonnelle E. Laboratory diagnosis of bacterial meningitis: usefulness of various tests for the determination of the etiological agent. Med Mal Infect. 2009;39(7–8): 581–605. 10.1016/j.medmal.2009.02.017
    1. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf.2014;5(6): 229–41. 10.1177/2042098614554919
    1. Ministry of Health and Population, Egypt. Enhanced Surveillance for Communicable Diseases, annual summary January- December 2000 report.[]. US Department of Defense Global Emerging Infections Surveillance and Response System, 2000.
    1. Youssef FG, El-Sakka H, Azab A, Eloun S, Chapman GD, Ismail T, et al. Etiology, antimicrobial susceptibility profiles, and mortality associated with bacterial meningitis among children in Egypt. Ann Epidemiol.2004;14(1):44–8.
    1. Afifi S, Wasfy MO, Azab MA, Youssef FG, Pimentel G, Graham TW, et al. Laboratory based surveillance of patients with bacterial meningitis in Egypt (1998–2004).Eur J Clin Microbiol Infect Dis.2007;26(5):331–40. 10.1007/s10096-007-0280-x
    1. Boctor WM.Statistical analysis of bacterial meningitis at embaba fever hospital.J Egypt Public Health Assoc.1969;44(4):253–9.
    1. Girgis NI, Yassin MW, Sanborn WR, Burdick RE, El-Ela HA, Kent DC, et al.Ampicillin compared with penicillin and chloramphenicol combined in the treatment of bacterial meningitis. J Trop Med Hyg.1972;75(8):154–7.
    1. Miner WF, Edman DC. Acute bacterial meningitis in Cairo, Arab Republic of Egypt, 1 January 1971 through 31 December 1975. Am J Trop Med Hyg 1978;27(5):986–94.
    1. Girgis NI, Sippel JE, Kilpatrick ME, Sanborn WR, Mikhail IA, Cross E, et al. Meningitis and encephalitis at the Abbassia fever hospital, Cairo, Egypt, from 1966 to 1989. Am J Trop Med Hyg.1993;48(1):97–107.
    1. Shaban L, and Siam R. Prevalence and antimicrobial resistance pattern of bacterial meningitis in Egypt. Ann Clin Microbiol Antimicrob. 2009;8:26 10.1186/1476-0711-8-26
    1. Jones ME, Draghi DC, Karlowsky JA, Sahm DF, Bradley JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002.Ann Clin Microbiol Antimicrob. 2004; 3:3 ()
    1. Owusu M, Nguah SB, Boaitey YA, Badu-Boateng E, Abubakr A, Lartey RA, et al. Aetiological agents of cerebrospinal meningitis: a retrospective study from a teaching hospital in Ghana. Ann ClinMicrobiolAntimicrob. 2012; 11:28 ().
    1. Auburtin M, Wolff M, Charpentier J, Varon E, Le Tulzo Y,Girault C, et al. Detrimental role of delayed antibiotic administration and penicillin-non susceptible strains in adult intensive care unit patients with pneumococcal meningitis: The PNEUMOREA prospective multicenter study. J Crit Care Med.2006;34(11):2758–65.
    1. Ostroff SM, Harrison LH, Khallaf N, Assaad MT, Guirguis NI, Harrington S, et al. Resistance patterns of Streptococcus pneumoniae and Haemophilus influenzae isolates recovered in Egypt from children with pneumonia. The antimicrobial resistance surveillance study group. Clin Infect Dis.1996;23(5):1069–74.
    1. El Kholy A, Baseem H, Hall GS, Procop GW, Longworth DL.Antimicrobial resistance in Cairo, Egypt 1999–2000: A survey of five hospitals. Antimicrob Agents Chemother.2003;51(3):625–30.
    1. Borg MA, Tiemersma E, Scicluna E, Sande-Bruinsma N van de, de Kraker M, Monen J, et al. Prevalence of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae isolates reported by laboratories in the southern and eastern mediterranean region. ClinMicrobiol Infect.2009;15(3):232–7.
    1. Taha N, Araj GF, Wakim RH, Kanj SS, Kanafani ZA, Sabra A, et al. Genotypes and serotype distribution of macrolide resistant invasive and non-invasive Streptococcus pneumoniae isolates from Lebanon. Ann Clin MicrobiolAntimicrob.2012; 11:2.
    1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev.1996;9(2):148–165.
    1. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumanniiin health care facilities.Clin Infect Dis.2006;42(5):692–9. 10.1086/500202
    1. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M. Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse.2008; 28(1):15–25.
    1. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam.Lancet.1994;344(8933):1329–32.
    1. Bergogne-Bérézin E: The increasing significance of outbreaks of Acinetobacter spp: the need for control and new agents. J Hosp Infect.1995;30(1):441–52.
    1. Frnández-Cuenca F, Martínez-Martínez L, Conejo MC, Ayala JA, Perea EJ, Pascual A.Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother.2003;51(3):565–74.
    1. Manchanda V, Sanchaita S, Singh N. Multidrug Resistant Acinetobacter.J Glob Infect Dis.2010, 2(3):291–304. 10.4103/0974-777X.68538
    1. Sader HS, Jones RN. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int J Antimicrob Agents. 2005;25(5):380–4. 10.1016/j.ijantimicag.2005.01.011
    1. Zhao C, Xie W, Zhang W, Ye Z, Wu H. Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro. J Zhonghua Shao Shang ZaZhi. 2014;30(2):166–70.
    1. Hirsch EB,Guo B,Chang KT,Cao H,Ledesma KR,Singh M,Tam VH. Assessment of Antimicrobial Combinations for Klebsiella pneumoniae Carbapenemase–Producing K.pneumoniae. J Infect Dis.( 2013);207(5):786–793.
    1. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.J Infect Control Hosp Epidemiol. 2009;30(12):1180.–.
    1. Hou XH, Song XY, Ma XB, Zhang SY, Zhang JQ. Molecular characterization of multidrug-resistant Klebsiella pneumoniae isolates. Braz J. Microbiol.2015;46(3):759–68. 10.1590/S1517-838246320140138
    1. Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes.Clin Infect Dis 2004;38(12):1736–41. 10.1086/421094
    1. Lewis JS II, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother.2007;51(11):4015–21. 10.1128/AAC.00576-07
    1. McGettigan SE, Hu B, Andreacchio K, Nachamkin I, Edelstein PH. Prevalence of CTX-M beta-lactamases in Philadelphia, Pennsylvania.J ClinMicrobiol.2009;47(9):2970–4
    1. Sidjabat HE,Paterson DL, Adams-Haduch JM, Ewan L, Pasculle AW, Muto CA, et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob. Agents Chemother. 2009; 53(11):4733–39. 10.1128/AAC.00533-09
    1. Peirano G, Costello M, Pitout JD. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. Int J Antimicrob Agents. 2010;36(1):19–23. 10.1016/j.ijantimicag.2010.02.016
    1. Chandramohan L, Revell PA. Prevalence and Molecular Characterization of Extended-Spectrum-β-Lactamase Producing Enterobacteriaceae in a Pediatric Patient Population. Antimicrob Agents Chemother.2012;56(9):4765–4770. 10.1128/AAC.00666-12
    1. Hooper DC. Mechanisms of quinolone resistance.DrugResistUpdat.1999; 2(1):38–55.
    1. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis.2000;31(2):S24–8.
    1. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of aac(6′)-Ib-cr Encoding a Ciprofloxacin-Modifying Enzyme.Antimicrob Agents Chemother. 2006;50(11):3953–3955. 10.1128/AAC.00915-06
    1. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid.Lancet.1998;351(9105):797–9. 10.1016/S0140-6736(97)07322-4

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere